Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Health Psychology Review
|
April 16, 2026
Meditation and workplace health: a systematic review and meta-analysis of mental and cardiometabolic outcomes among employees
Mahesh Kumar Khanal, Peter Saunders, Kathy Nguyen, et al.
Trials
|
June 17, 2017
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
Peter Saunders, Vicky Tsipouri, Gregory J Keir, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 29, 2020
BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study
Philip L Molyneaux, Jonathan J Smith, Peter Saunders, et al.
American Journal of Respiratory and Critical Care Medicine
|
May 4, 2019
The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis
Sarah J Allden, Patricia P Ogger, Poonam Ghai, et al.
The Lancet. Respiratory Medicine
|
November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
Toby M Maher, Veronica A Tudor, Peter Saunders, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 1, 2022
CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort
Philip L Molyneaux, William A Fahy, Adam J Byrne, et al.
Annals of the American Thoracic Society
|
May 9, 2023
The Burden and Impact of Cough in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the Prospective Observational PROFILE Study
Peter Saunders, Zhe Wu, William A Fahy, et al.
Science Immunology
|
October 24, 2020
Itaconate controls the severity of pulmonary fibrosis
Patricia P Ogger, Gesa J Albers, Richard J Hewitt, et al.
ERJ Open Research
|
March 23, 2023
Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
Lavanya Raman, Iain Stewart, Shaney L Barratt, et al.
The European Respiratory Journal
|
February 16, 2019
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Pauline T Lukey, Stephen A Harrison, Shuying Yang, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Health Psychology Review
|
April 16, 2026
Meditation and workplace health: a systematic review and meta-analysis of mental and cardiometabolic outcomes among employees
Mahesh Kumar Khanal, Peter Saunders, Kathy Nguyen, et al.
Trials
|
June 17, 2017
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
Peter Saunders, Vicky Tsipouri, Gregory J Keir, et al.
American Journal of Respiratory and Critical Care Medicine
|
August 29, 2020
BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study
Philip L Molyneaux, Jonathan J Smith, Peter Saunders, et al.
American Journal of Respiratory and Critical Care Medicine
|
May 4, 2019
The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis
Sarah J Allden, Patricia P Ogger, Poonam Ghai, et al.
The Lancet. Respiratory Medicine
|
November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
Toby M Maher, Veronica A Tudor, Peter Saunders, et al.
American Journal of Respiratory and Critical Care Medicine
|
April 1, 2022
CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort
Philip L Molyneaux, William A Fahy, Adam J Byrne, et al.
Annals of the American Thoracic Society
|
May 9, 2023
The Burden and Impact of Cough in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the Prospective Observational PROFILE Study
Peter Saunders, Zhe Wu, William A Fahy, et al.
Science Immunology
|
October 24, 2020
Itaconate controls the severity of pulmonary fibrosis
Patricia P Ogger, Gesa J Albers, Richard J Hewitt, et al.
ERJ Open Research
|
March 23, 2023
Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
Lavanya Raman, Iain Stewart, Shaney L Barratt, et al.
The European Respiratory Journal
|
February 16, 2019
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Pauline T Lukey, Stephen A Harrison, Shuying Yang, et al.
Page
of 4